CN106659723A - 用于治疗神经病症的方法 - Google Patents

用于治疗神经病症的方法 Download PDF

Info

Publication number
CN106659723A
CN106659723A CN201580037336.8A CN201580037336A CN106659723A CN 106659723 A CN106659723 A CN 106659723A CN 201580037336 A CN201580037336 A CN 201580037336A CN 106659723 A CN106659723 A CN 106659723A
Authority
CN
China
Prior art keywords
rats
patient
dose
day
dementia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580037336.8A
Other languages
English (en)
Chinese (zh)
Inventor
约翰·贾汉吉尔·阿拉姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EIP Pharma LLC
Original Assignee
EIP Pharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EIP Pharma LLC filed Critical EIP Pharma LLC
Priority to CN202110348688.2A priority Critical patent/CN113018300B/zh
Priority to CN202110783304.XA priority patent/CN114010641A/zh
Publication of CN106659723A publication Critical patent/CN106659723A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580037336.8A 2014-07-09 2015-07-08 用于治疗神经病症的方法 Pending CN106659723A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202110348688.2A CN113018300B (zh) 2014-07-09 2015-07-08 用于治疗神经病症的方法
CN202110783304.XA CN114010641A (zh) 2014-07-09 2015-07-08 用于治疗神经病症的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462022586P 2014-07-09 2014-07-09
US62/022,586 2014-07-09
PCT/US2015/039539 WO2016007616A1 (en) 2014-07-09 2015-07-08 Methods for treating neurologic disorders

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202110783304.XA Division CN114010641A (zh) 2014-07-09 2015-07-08 用于治疗神经病症的方法
CN202110348688.2A Division CN113018300B (zh) 2014-07-09 2015-07-08 用于治疗神经病症的方法

Publications (1)

Publication Number Publication Date
CN106659723A true CN106659723A (zh) 2017-05-10

Family

ID=55064826

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201580037336.8A Pending CN106659723A (zh) 2014-07-09 2015-07-08 用于治疗神经病症的方法
CN202110348688.2A Active CN113018300B (zh) 2014-07-09 2015-07-08 用于治疗神经病症的方法
CN202110783304.XA Pending CN114010641A (zh) 2014-07-09 2015-07-08 用于治疗神经病症的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202110348688.2A Active CN113018300B (zh) 2014-07-09 2015-07-08 用于治疗神经病症的方法
CN202110783304.XA Pending CN114010641A (zh) 2014-07-09 2015-07-08 用于治疗神经病症的方法

Country Status (5)

Country Link
US (1) US9579322B2 (https=)
EP (1) EP3166610B1 (https=)
JP (1) JP6660369B2 (https=)
CN (3) CN106659723A (https=)
WO (1) WO2016007616A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108348524A (zh) * 2015-10-26 2018-07-31 爱普制药有限责任公司 用于从中风恢复的方法和组合物
CN113329754A (zh) * 2018-11-20 2021-08-31 麻雀制药股份有限公司 用于施用皮质类固醇的方法
CN113616795A (zh) * 2021-08-31 2021-11-09 上海交通大学医学院附属瑞金医院 Pp2a激动剂防治由正常衰老或pp2a活性或表达降低所导致的精神障碍
US11466008B2 (en) 2017-09-18 2022-10-11 Eip Pharma, Llc Co-crystals of neflamapimod (VX-745)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106659723A (zh) 2014-07-09 2017-05-10 爱普制药有限责任公司 用于治疗神经病症的方法
EP3445369B1 (en) 2016-04-21 2026-03-25 Eip Pharma, LLC Vx-745 for use in the treatment of dementia
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019178153A1 (en) * 2018-03-12 2019-09-19 Eip Pharma, Llc Pharmaceutical formulations of neflamapimod
WO2020257333A1 (en) * 2019-06-18 2020-12-24 Opiant Pharmaceuticals, Inc. Compositions and methods for treating acute cannabinoid overdose with a cannabinoid receptor antagonist
AU2020296012A1 (en) 2019-06-18 2022-01-20 Indivior Uk Limited Compositions and methods for treating cannabinoid hyperemesis syndrome with a cannabinoid receptor antagonist
CN115066245A (zh) * 2019-07-12 2022-09-16 Eip制药公司 用于治疗路易体痴呆的组合物和方法
CN116801887A (zh) * 2020-11-06 2023-09-22 Eip制药公司 治疗神经退行性疾病的步态功能障碍
IL311960A (en) * 2021-11-05 2024-06-01 Eip Pharma Llc Treatment of a selective population of patients suffering from dementia with Lewy bodies
AU2024263955A1 (en) * 2023-04-27 2025-11-20 Remepy Health Ltd Digital therapeutics

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103842362A (zh) * 2011-05-09 2014-06-04 爱普制药有限责任公司 用于治疗阿尔茨海默氏病的组合物和方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147080A (en) 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
CN100571701C (zh) * 2002-12-24 2009-12-23 贝卢斯健康(国际）有限公司 治疗β淀粉样蛋白相关疾病的治疗性制品
WO2005091891A2 (en) 2004-03-11 2005-10-06 Kythera Biopharmaceuticals, Inc. Compositions and methods for preventing and treating skin and hair conditions
US20050203111A1 (en) 2004-03-12 2005-09-15 Vvii Newco 2003, Inc. Compositions and methods for preventing and treating skin and hair conditions
CA2627599A1 (en) * 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Process for (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
US20110201686A1 (en) 2006-06-23 2011-08-18 Yousef Al-Abed Inhibitors of ASS and Synuclein Aggregation
CA2726588C (en) 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
US20140163026A1 (en) * 2011-04-08 2014-06-12 Afraxis Holdings, Inc. 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of nervous system disorders and cancer
CN106659723A (zh) 2014-07-09 2017-05-10 爱普制药有限责任公司 用于治疗神经病症的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103842362A (zh) * 2011-05-09 2014-06-04 爱普制药有限责任公司 用于治疗阿尔茨海默氏病的组合物和方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KUMAR S等: "p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases", 《NATURE REVIEWS DRUG DISCOVERY》 *
张孝娟等主编: "《中医临床心理学》", 30 June 2006, 中国医药科技出版社 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108348524A (zh) * 2015-10-26 2018-07-31 爱普制药有限责任公司 用于从中风恢复的方法和组合物
US11466008B2 (en) 2017-09-18 2022-10-11 Eip Pharma, Llc Co-crystals of neflamapimod (VX-745)
CN113329754A (zh) * 2018-11-20 2021-08-31 麻雀制药股份有限公司 用于施用皮质类固醇的方法
CN113616795A (zh) * 2021-08-31 2021-11-09 上海交通大学医学院附属瑞金医院 Pp2a激动剂防治由正常衰老或pp2a活性或表达降低所导致的精神障碍
CN113616795B (zh) * 2021-08-31 2023-06-20 上海交通大学医学院附属瑞金医院 Pp2a激动剂防治由正常衰老或pp2a活性或表达降低所导致的精神障碍

Also Published As

Publication number Publication date
CN113018300A (zh) 2021-06-25
US9579322B2 (en) 2017-02-28
EP3166610A1 (en) 2017-05-17
WO2016007616A1 (en) 2016-01-14
CN114010641A (zh) 2022-02-08
US20160008364A1 (en) 2016-01-14
CN113018300B (zh) 2025-11-25
JP2017519807A (ja) 2017-07-20
JP6660369B2 (ja) 2020-03-11
EP3166610A4 (en) 2017-11-29
EP3166610B1 (en) 2022-11-02

Similar Documents

Publication Publication Date Title
US9579322B2 (en) Methods for treating neurologic disorders
CN103842362B (zh) 用于治疗阿尔茨海默氏病的组合物和方法
RU2338533C1 (ru) СРЕДСТВО, ОБЛАДАЮЩЕЕ АНКСИОЛИТИЧЕСКИМ ДЕЙСТВИЕМ, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
JP6535727B2 (ja) 骨格筋疲労に対する耐性を向上させるための方法
TWI582079B (zh) σ配體類於與第２型糖尿病有關之疼痛上之用途
AU2007229322A1 (en) Method of treatment or prophylaxis inflammatory pain
KR102891465B1 (ko) 뇌졸중으로부터의 회복을 위한 방법 및 조성물
KR20170106485A (ko) 요산 또는 통풍 질환의 예방 또는 치료
HK40068517A (en) Methods for treating neurologic disorders
JP2006513207A (ja) 行動障害の治療のためのイストラデフィリン（ｋｗ−６００２）の使用
JP2023060147A (ja) ５－ｈｔ４受容体アゴニストの新しい使用
HK40019123A (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
HK1260485A1 (en) Methods and compositions for recovery from stroke
HK1230184B (en) Compositions and methods for treating alzheimer's disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170510